Paper385138
Etoposide (VP-16-213).
Issell BF and 1 other. Cancer Treat Rev, 1979. Cited by 170 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Etoposide (VP-16-213). Papers, record 385138. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/385138
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Etoposide | Major topic |
| Neoplasms | Major topic |
| Podophyllotoxin | Major topic |
| Adult | |
| Animals | |
| Bone Marrow | |
| Cell Cycle | |
| Child | |
| Digestive System | |
| Drug Therapy, Combination | |
| Female | |
| Humans | |
| Leukemia | |
| Lung Neoplasms | |
| Lymphoma | |
| Male | |
| Mice | |
| Neoplasms, Experimental | |
| Rats |
Source PubMed
Cited by38
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 170 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,766,523 | A Critical Analysis of the Impact of Etoposide as a Topoisomerase II Inhibitor in Cervical Cancer Treatment: A Review. | Cancer Med | 2026 | https://conductscience.org/library/papers/41766523 | PubMed |
| 41,384,121 | Cure of a CD20-positive peripheral T-cell lymphoma-NOS with CHOPE regimen plus surgery a case report and literature review. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/41384121 | PubMed |
| 39,981,182 | A review on intrathecal administration of medications for leptomeningeal metastases in solid tumors. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/39981182 | PubMed |
| 21,822,607 | A new iridoid glycoside and NO production inhibitory activity of compounds isolated from Russelia equisetiformis. | J Nat Med | 2012 | https://conductscience.org/library/papers/21822607 | PubMed |
| 21,240,679 | Constituents of cultivated Agaricus blazei. | J Nat Med | 2011 | https://conductscience.org/library/papers/21240679 | PubMed |
| 18,409,065 | Rearranged ent-kauranes from the stems of Tricalysia dubia and their biological activities. | J Nat Med | 2008 | https://conductscience.org/library/papers/18409065 | PubMed |
| 10,711,848 | Oral combination chemotherapy in the management of AIDS-related lymphoproliferative malignancies. | Drugs | 1999 | https://conductscience.org/library/papers/10711848 | PubMed |
| 8,690,756 | Analysis of thrombocytopenia due to carboplatin combined with etoposide in elderly patients with lung cancer. | J Cancer Res Clin Oncol | 1996 | https://conductscience.org/library/papers/8690756 | PubMed |
| 7,781,140 | Safety and efficacy of intraperitoneal injection of etoposide in oil suspension in mice with peritoneal carcinomatosis. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7781140 | PubMed |
| 7,083,463 | Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7083463 | PubMed |
| 7,083,454 | Pharmacokinetics of VP16-213 given by different administration methods. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7083454 | PubMed |
| 7,083,453 | Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7083453 | PubMed |
| 7,083,452 | Interaction of VP16-213 with the DNA repair antagonist chloroquine. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7083452 | PubMed |
| 7,083,450 | Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7083450 | PubMed |
| 7,044,596 | Current development of podophyllotoxins. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7044596 | PubMed |
| 7,044,594 | VP16-213 (etoposide). A critical review of its activity. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7044594 | PubMed |
| 7,044,593 | The podophyllotoxin derivatives VP16-213 and VM26. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7044593 | PubMed |
| 7,044,592 | The clinical pharmacology of VM26 and VP16-213. A brief overview. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7044592 | PubMed |
| 7,044,591 | VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7044591 | PubMed |
| 7,031,350 | [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)]. | Klin Wochenschr | 1981 | https://conductscience.org/library/papers/7031350 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/385138
GET https://conductscience.org/api/papers/v1/385138/cited_by?page=2